Early results encouraging in study of adalimumab for hidradenitis suppurativa
October 21st 2014New results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug.